Spark Therapeutics, Inc. (ONCE) Shares Bought by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. lifted its position in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 8.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 94,920 shares of the biotechnology company’s stock after buying an additional 7,169 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.30% of Spark Therapeutics worth $5,671,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Spark Therapeutics by 0.9% during the 1st quarter. FMR LLC now owns 4,656,655 shares of the biotechnology company’s stock worth $248,386,000 after buying an additional 40,698 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Spark Therapeutics by 10.9% during the 1st quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock worth $5,923,000 after buying an additional 10,916 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Spark Therapeutics by 81.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock worth $1,507,000 after buying an additional 11,335 shares during the last quarter. American International Group Inc. increased its holdings in shares of Spark Therapeutics by 17.4% during the 1st quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock worth $618,000 after buying an additional 1,714 shares during the last quarter. Finally, Nationwide Fund Advisors increased its holdings in shares of Spark Therapeutics by 2.5% during the 1st quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after buying an additional 414 shares during the last quarter. Institutional investors and hedge funds own 77.84% of the company’s stock.

In related news, insider Daniel Faga sold 3,000 shares of Spark Therapeutics stock in a transaction on Monday, July 24th. The shares were sold at an average price of $70.00, for a total value of $210,000.00. Following the transaction, the insider now owns 3,000 shares in the company, valued at approximately $210,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Anand Mehra sold 211,858 shares of Spark Therapeutics stock in a transaction on Monday, July 24th. The stock was sold at an average price of $70.15, for a total transaction of $14,861,838.70. The disclosure for this sale can be found here. Insiders sold a total of 1,333,195 shares of company stock worth $109,070,506 in the last quarter. Insiders own 7.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics, Inc. (ONCE) Shares Bought by Schwab Charles Investment Management Inc.” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://sportsperspectives.com/2017/10/13/spark-therapeutics-inc-once-shares-bought-by-schwab-charles-investment-management-inc.html.

Spark Therapeutics, Inc. (NASDAQ ONCE) opened at 86.20 on Friday. The firm has a 50-day moving average of $85.92 and a 200-day moving average of $85.92. Spark Therapeutics, Inc. has a 52-week low of $35.07 and a 52-week high of $91.00. The stock’s market capitalization is $2.69 billion.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing the consensus estimate of ($1.75) by ($0.14). The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business’s revenue was up 14.7% compared to the same quarter last year. During the same quarter last year, the business earned ($1.04) EPS. On average, equities analysts expect that Spark Therapeutics, Inc. will post ($7.67) EPS for the current year.

A number of analysts have recently commented on the company. BMO Capital Markets restated an “outperform” rating and set a $89.00 price objective (up from $69.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Chardan Capital raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $60.00 to $100.00 in a research report on Tuesday, August 8th. Cowen and Company reaffirmed an “outperform” rating and set a $95.00 price target (up from $75.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Zacks Investment Research cut shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, UBS AG reaffirmed a “buy” rating and set a $92.00 price target (up from $70.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $88.81.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics, Inc. (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply